


### Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Currently amended) A combination product comprising as pharmaceutically active ingredients at least one active ingredient component A and at least one active ingredient component B, ~~characterized in that~~ wherein active ingredient component A is a direct stimulator of soluble guanylate cyclase ~~of~~ having the formula (I)



in which

$R^1$  is  $-NR^3C(=O)OR^4$ ,

$R^2$  is hydrogen or  $NH_2$ ,

$R^3$  is hydrogen or  $(C_1-C_4)$ -alkyl,

$R^4$  is  $(C_1-C_6)$ -alkyl,

and active ingredient component B is a lipid-lowering agent.


2. (Currently amended) The combination product as claimed in claim 1,

~~where~~ wherein

$R^1$  is  $-NR^3C(=O)OR^4$ ,

$R^2$  is  $NH_2$ ,  
 $R^3$  is methyl or ethyl, and  
 $R^4$  is methyl, ethyl or isopropyl.

3. (Currently amended) The combination product as claimed in claim 1, ~~where~~ wherein the direct stimulator of soluble guanylate cyclase of the formula (I) has the following structure:



4. Cancelled
5. Cancelled
6. (Currently amended) The combination product as claimed in any of claims 1 to 3 [[5]], ~~characterized in that~~ wherein the active ingredient components A and B are in the form of a functional unit~~[[,]] in particular in the form of a mixture, of a mix or of a blend.~~
7. (Currently amended) The combination product as claimed in ~~any of claims 1 to 6~~ claim 1, ~~characterized in that~~ wherein the active ingredient components A and B are (spatially) separate from one another, ~~in particular~~ in the form of a kit of parts.

8. (Currently amended) The combination product as claimed in ~~any of claims 1 to 7~~ claim 1, ~~characterized in that~~ wherein the lipid-lowering agent (active ingredient component B) is selected from the group consisting of (a) HMG-CoA-reductase inhibitors; (b) squalene synthase inhibitors; (c) bile acid absorption inhibitors (bile acid sequestrants); (d) fibric acid and its derivatives; (e) nicotinic acid and its analogs; and (f)  $\omega$ 3-fatty acids.
9. (Currently amended) The combination product as claimed in claim 8, ~~characterized in that~~ wherein the lipid-lowering agent (active ingredient component B) is an HMG-CoA reductase inhibitor and is selected ~~in particular~~ from the group of statins, ~~preferably from the group of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, simvastatin and rosuvastatin, and their respective salts, hydrates, alcohols, esters and tautomers.~~
10. (Currently amended) The combination product as claimed in claim ~~[[9]]~~ 26, ~~characterized in that~~ wherein the lipid-lowering agent (active ingredient component B) is atorvastatin or its salt, hydrate, alcoholate, ester ~~and~~ or tautomer.
11. (Currently amended) The combination product as claimed in claim ~~[[9]]~~ 26, ~~characterized in that~~ wherein the lipid-lowering agent (active ingredient component B) is cerivastatin or its salt, hydrate, alcoholate, ester ~~and~~ or tautomer.
12. (Currently amended) ~~The use of lipid-lowering agents~~ A method for increasing the efficacy of direct soluble guanylate cyclase stimulators of the formula (I) as defined in claim 1 comprising administering a lipid-lowering agent in conjunction with said direct soluble guanylate cyclase stimulator of formula (I).
13. (Currently amended) A process for producing compositions as claimed in ~~any of claims 1 to 12~~ claim 1, ~~characterized in that~~ comprising converting at least one lipid-lowering

agent and at least one direct soluble guanylate cyclase stimulator of the formula (I) is ~~converted~~, where appropriate with conventional excipients and additives, into a suitable administration form.

14. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of cardiovascular disorders comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
15. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of hypertension comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
16. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of thromboembolic disorders and ischemias comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
17. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of sexual dysfunction comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.

18. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of arteriosclerosis comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
19. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of osteoporosis comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
20. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments having an antiinflammatory effect~~ A method for the treatment of inflammation comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
21. (Currently amended) ~~The use of compositions as claimed in any of claims 1 to 12 in the production of medicaments~~ A method for the treatment of central nervous system disorders comprising administering an effective amount of a combination of a direct stimulator of soluble guanylate cyclase of formula (I) and a lipid-lowering agent as defined in claim 1, 2, 3, 6, 7, 8, 9, 10, or 11.
22. (Currently amended) The use method as claimed in any of claims 14 to 21, where the ~~compositions as claimed in any of claims 1 to 13~~ direct stimulator of soluble guanylate cyclase of formula (I) and the lipid-lowering agent are employed in combination with organic nitrates or NO donors or in combination with compounds which inhibit the breakdown of cyclic guanosine monophosphate (cGMP).

23. (New) The combination product as claimed in claim 6 wherein said functional unit is a mixture, mix, or blend.
24. (New) The combination product of claim 7 wherein the separation of active ingredient components A and B permits them to be separately administered either simultaneously or sequentially.
25. (New) The combination product of claim 24 wherein the separation of active ingredient components A and B permits them to be separately administered sequentially.
26. (New) The combination product as claimed in claim 8, wherein the lipid-lowering agent is selected from the group of statins consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, pitavastatin, simvastatin and rosuvastatin, and their respective salts, hydrates, alcohols, esters and tautomers